Michael A. Insko

Michael A. Insko has a long history of work experience in the pharmaceutical industry. Michael A. began their career in 1997 as a Student Lab Assistant at Metabasis Therapeutics (Gensia Pharmaceuticals, Inc.), where they assisted in acute myocardial infarction studies and evaluated the glucose lowering effects of small molecules in diabetic rats. Michael A. then moved to Ambit Biosciences in 2000 as a Senior Research Associate, where they were a key team member involved in the generation and optimization of kinase assays. In 2004, they joined Ikaria, Inc. as an Associate Scientist, where they performed proof of concept studies in rodents to indicate intravenously administered sodium sulfide is exhaled as hydrogen sulfide (H2S) gas. Michael A. then moved to Oncothyreon, Inc. in 2012 as a Research Associate, where they characterized small molecules in vitro and developed assays to assess Phase I & II metabolism. Finally, in 2014, they joined Faraday Pharmaceuticals, Inc. as Director, Scientific Affairs & Advocate Development, Director, Preclinical Sciences, and Senior Scientist. In these roles, they managed in-house facilities, oversaw external pre-clinical projects, wrote scientific reports, and developed in vivo critical care models.

Michael A. Insko's education history includes a Bachelor of Science degree in Animal Physiology & Neuroscience with a minor in Theatre from UC San Diego from 1996-2000. Michael A. is currently pursuing a Master of Science degree in Translational Pharmacology from The Ohio State University from 2021-2023. Prior to this, they attended University City High School from 1992-1996. In addition, they have obtained various certifications, including "From the Laboratory to Leadership" from The Leadership Edge in April 2021, "Introduction to Phoenix WinNonlin" from Certara in April 2016, "Good Clinical Practice [GCP] (US FDA Focus)" from the CITI Program in September 2022, "Laboratory Animal Technologist (LATG/RLATG)" from AALAS in January 2022, "Good Laboratory Practice" from the CITI Program in September 2022, "Laboratory Animal Technician (LAT/RLAT)" from AALAS in February 2021, and "Assistant Laboratory Animal Technician (ALAT/RALAT)" from AALAS in December 2020.